Inventaire - your friends and communities are your best library

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Author

Massimo Loda

Todd Golub

Judith Manola

Published in: Nature medicine

Date of publication: May 23, 2004

Language: English

Main subject: apoptotic process, intraepithelial neoplasia

Bibliographic databases:

Cites articles 36

Date

Title

Authors

January 1, 1994

Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients
December 1, 1995

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

,
October 24, 1997

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt,Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt
May 1, 1998

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

,
April 1, 1999

Direct control of the Forkhead transcription factor AFX by protein kinase B
December 1, 1999

Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway
January 1, 1999

PIK3CA is implicated as an oncogene in ovarian cancer.

, ,
July 1, 1999

Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies
December 1, 2000

Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.
November 1, 2000

Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin
February 1, 2000

Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI.
May 1, 2000

The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo
January 1, 2000

Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia.
December 1, 2000

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
August 28, 2001

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
August 14, 2001

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice
June 1, 2001

TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth
May 1, 2001

Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size
August 8, 2001

PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression
July 1, 2002

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

,
September 1, 2002

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling
February 1, 2002

Early clinical experience with a novel rapamycin derivative
September 2002

Signal transduction to hypoxia-inducible factor 1
October 1, 2002

The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini

, ,
July 1, 2002

Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake
October 1, 2002

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin

, ,
May 24, 2002

Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway
August 5, 2003

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

,
June 10, 2003

Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model

, ,
July 2003

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

, , , , , ,
October 20, 2003

Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner

,
June 1, 2003

Mammalian target of rapamycin: a new molecular target for breast cancer

Article -

Welcome to inventaire

The library of your friends and communities

You are offline